![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 15, Issue 12, 5693-5699, December 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Department of Physiology, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, 6500 HB Nijmegen, The Netherlands;
Department of Human Genetics, University Medical Center Nijmegen, 6500 HB Nijmegen, The Netherlands
Submitted April 23, 2004;
Revised September 21, 2004;
Accepted September 23, 2004
Monitoring Editor: Keith Mostov
Binding of arginine-vasopressin (AVP) to its V2 receptor (V2R) in the basolateral membrane of principal cells induces Aquaporin-2–mediated water reabsorption in the kidney. To study the regulation of the V2R by dDAVP in a proper model, a polarized renal cell line stably-expressing V2R-GFP was generated. Labeled AVP-binding studies revealed an equal basolateral vs. apical membrane distribution for V2R-GFP and endogenous V2R. In these cells, GFP-V2R was expressed in its mature form and localized for 75% in the basolateral membrane and for 25% to late endosomes/lysosomes. dDAVP caused a dose- and time-dependent internalization of V2R-GFP, which was completed within 1 h with 100 nM dDAVP, was prevented by coincubation with a V2R antagonist, and which reduced its half-life from 11.5 to 2.8 h. Semiquantification of the V2R-GFP colocalization with E-cadherin (basolateral membrane), early endosomal antigen-1 (EEA-1) and lysosome-associated membrane protein-2 (LAMP-2) in time revealed that most dDAVP-bound V2R was internalized via early endosomes to late endosomes/lysosomes, where it was degraded. The dDAVP-internalized V2R did not recycle to the basolateral membrane. In conclusion, we established the itinerary of the V2R in a polarized cell model that likely resembles the in vivo V2R localization and regulation by AVP to a great extent.
Corresponding author. E-mail address: p.deen{at}ncmls.ru.nl.
This article has been cited by other articles:
|
|
 |
|
  M. Faerch, J. H. Christensen, S. Rittig, J.-O. Johansson, N. Gregersen, F. de Zegher, and T. J. Corydon Diverse vasopressin V2 receptor functionality underlying partial congenital nephrogenic diabetes insipidus Am J Physiol Renal Physiol, December 1, 2009; 297(6): F1518 - F1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Jean-Alphonse, S. Perkovska, M.-C. Frantz, T. Durroux, C. Mejean, D. Morin, S. Loison, D. Bonnet, M. Hibert, B. Mouillac, et al. Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus J. Am. Soc. Nephrol., October 1, 2009; 20(10): 2190 - 2203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Robben, M. L. A. Kortenoeven, M. Sze, C. Yae, G. Milligan, V. M. Oorschot, J. Klumperman, N. V. A. M. Knoers, and P. M. T. Deen Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists PNAS, July 21, 2009; 106(29): 12195 - 12200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Cliffe, J. M. Kramer, K. Hussain, J. H. Robben, E. K. de Jong, A. P. de Brouwer, E. Nibbeling, E.-J. Kamsteeg, M. Wong, J. Prendiville, et al. SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-dependent diabetes mellitus syndrome and interacts with the insulin signaling pathway Hum. Mol. Genet., June 15, 2009; 18(12): 2257 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Schwieger, K. Lautz, E. Krause, W. Rosenthal, B. Wiesner, and R. Hermosilla Derlin-1 and p97/Valosin-Containing Protein Mediate the Endoplasmic Reticulum-Associated Degradation of Human V2 Vasopressin Receptors Mol. Pharmacol., March 1, 2008; 73(3): 697 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yangthara, A. Mills, V. Chatsudthipong, L. Tradtrantip, and A. S. Verkman Small-Molecule Vasopressin-2 Receptor Antagonist Identified by a G-Protein Coupled Receptor "Pathway" Screen Mol. Pharmacol., July 1, 2007; 72(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Robben, M. Sze, N. V. Knoers, P. Eggert, P. Deen, and D. Muller Relief of Nocturnal Enuresis by Desmopressin Is Kidney and Vasopressin Type 2 Receptor Independent J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1534 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Izumi, Y. Nakayama, T. Mori, H. Miyazaki, H. Inoue, Y. Kohda, T. Inoue, H. Nonoguchi, and K. Tomita Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1418 - F1426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yi, R. Bouley, H. Y. Lin, S. Bechoua, T.-x. Sun, E. del Re, T. Shioda, M. K. Raychowdhury, H. A. J. Lu, A. B. Abou-Samra, et al. Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1303 - F1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Robben, M. Sze, N. V. A. M. Knoers, and P. M. T. Deen Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus Am J Physiol Renal Physiol, January 1, 2007; 292(1): F253 - F260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, S. Shaw, E.-J. Kamsteeg, A. Vandewalle, and P. M.T. Deen Development of Lithium-Induced Nephrogenic Diabetes Insipidus Is Dissociated from Adenylyl Cyclase Activity J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1063 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Macion-Dazard, N. Callahan, Z. Xu, N. Wu, M. Thibonnier, and M. Shoham Mapping the Binding Site of Six Nonpeptide Antagonists to the Human V2-Renal Vasopressin Receptor J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 564 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Robben, M. Sze, N.V.A.M. Knoers, and P.M.T. Deen Rescue of Vasopressin V2 Receptor Mutants by Chemical Chaperones: Specificity and Mechanism Mol. Biol. Cell, January 1, 2006; 17(1): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Robben, N. V. A. M. Knoers, and P. M. T. Deen Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model Am J Physiol Renal Physiol, August 1, 2005; 289(2): F265 - F272. [Abstract] [Full Text] [PDF]
|
|
